Decision Impact Analysis to Measure the Influence of Molecular Signature Response Classifier Testing on Treatment Selection in Rheumatoid Arthritis.
Jeffrey R CurtisVibeke StrandSteven J GolombekGeorge A KarpouzasLixia ZhangAngus WongKrishna PatelJennifer DinesViatcheslav R AkmaevPublished in: Rheumatology and therapy (2023)
This study showed that rheumatologists reported using the MSRC test to guide b/tsDMARD selection for patients with RA. In most cases, MSRC test results appeared to influence clinical decision-making according to physician self-report. Wider adoption of precision medicine tools like the MSRC could support rheumatologists and patients in working together to achieve optimal outcomes for RA.
Keyphrases
- rheumatoid arthritis
- decision making
- end stage renal disease
- disease activity
- newly diagnosed
- ejection fraction
- chronic kidney disease
- emergency department
- primary care
- interstitial lung disease
- peritoneal dialysis
- prognostic factors
- type diabetes
- systemic lupus erythematosus
- metabolic syndrome
- insulin resistance
- combination therapy
- idiopathic pulmonary fibrosis
- weight loss